JP2017184729A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017184729A5 JP2017184729A5 JP2017046859A JP2017046859A JP2017184729A5 JP 2017184729 A5 JP2017184729 A5 JP 2017184729A5 JP 2017046859 A JP2017046859 A JP 2017046859A JP 2017046859 A JP2017046859 A JP 2017046859A JP 2017184729 A5 JP2017184729 A5 JP 2017184729A5
- Authority
- JP
- Japan
- Prior art keywords
- expression
- pde4d7
- prostate cancer
- sample
- level
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010060862 Prostate cancer Diseases 0.000 claims 23
- 239000000523 sample Substances 0.000 claims 22
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 18
- 238000000034 method Methods 0.000 claims 15
- 108090000623 proteins and genes Proteins 0.000 claims 14
- 238000003018 immunoassay Methods 0.000 claims 13
- 238000012544 monitoring process Methods 0.000 claims 12
- 206010062904 Hormone-refractory prostate cancer Diseases 0.000 claims 6
- 102000004169 proteins and genes Human genes 0.000 claims 6
- 239000005556 hormone Substances 0.000 claims 5
- 229940088597 hormone Drugs 0.000 claims 5
- 239000003446 ligand Substances 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 claims 3
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 claims 3
- 239000013068 control sample Substances 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 108091005461 Nucleic proteins Proteins 0.000 claims 2
- 230000004071 biological effect Effects 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 238000001514 detection method Methods 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 210000002307 prostate Anatomy 0.000 claims 2
- 210000002700 urine Anatomy 0.000 claims 2
- 108091023037 Aptamer Proteins 0.000 claims 1
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 claims 1
- 108700039887 Essential Genes Proteins 0.000 claims 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 claims 1
- 101001067140 Homo sapiens Porphobilinogen deaminase Proteins 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 1
- 102100034391 Porphobilinogen deaminase Human genes 0.000 claims 1
- 102000007066 Prostate-Specific Antigen Human genes 0.000 claims 1
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 239000002872 contrast media Substances 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 210000001808 exosome Anatomy 0.000 claims 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 210000003296 saliva Anatomy 0.000 claims 1
- 230000003248 secreting effect Effects 0.000 claims 1
- 239000013049 sediment Substances 0.000 claims 1
- 210000000582 semen Anatomy 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09159960 | 2009-05-12 | ||
| EP09159960.5 | 2009-05-12 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012510424A Division JP6148007B2 (ja) | 2009-05-12 | 2010-05-11 | 前立腺癌マーカーとしてのホスホジエステラーゼ４ｄ７ |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018205900A Division JP2019059733A (ja) | 2009-05-12 | 2018-10-31 | 前立腺癌マーカーとしてのホスホジエステラーゼ４ｄ７ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017184729A JP2017184729A (ja) | 2017-10-12 |
| JP2017184729A5 true JP2017184729A5 (enExample) | 2018-02-08 |
| JP6430560B2 JP6430560B2 (ja) | 2018-11-28 |
Family
ID=40843709
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012510424A Active JP6148007B2 (ja) | 2009-05-12 | 2010-05-11 | 前立腺癌マーカーとしてのホスホジエステラーゼ４ｄ７ |
| JP2015188247A Active JP6105012B2 (ja) | 2009-05-12 | 2015-09-25 | 前立腺癌マーカーとしてのホスホジエステラーゼ４ｄ７ |
| JP2017046859A Active JP6430560B2 (ja) | 2009-05-12 | 2017-03-13 | 前立腺癌マーカーとしてのホスホジエステラーゼ４ｄ７ |
| JP2018205900A Pending JP2019059733A (ja) | 2009-05-12 | 2018-10-31 | 前立腺癌マーカーとしてのホスホジエステラーゼ４ｄ７ |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012510424A Active JP6148007B2 (ja) | 2009-05-12 | 2010-05-11 | 前立腺癌マーカーとしてのホスホジエステラーゼ４ｄ７ |
| JP2015188247A Active JP6105012B2 (ja) | 2009-05-12 | 2015-09-25 | 前立腺癌マーカーとしてのホスホジエステラーゼ４ｄ７ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018205900A Pending JP2019059733A (ja) | 2009-05-12 | 2018-10-31 | 前立腺癌マーカーとしてのホスホジエステラーゼ４ｄ７ |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US8753892B2 (enExample) |
| EP (2) | EP2430191B1 (enExample) |
| JP (4) | JP6148007B2 (enExample) |
| KR (1) | KR101778036B1 (enExample) |
| CN (2) | CN107267482A (enExample) |
| BR (1) | BRPI1007093A2 (enExample) |
| DK (1) | DK2430191T3 (enExample) |
| ES (1) | ES2700877T3 (enExample) |
| RU (1) | RU2651474C2 (enExample) |
| WO (1) | WO2010131195A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3343647B2 (ja) | 1997-07-22 | 2002-11-11 | 株式会社岡田建築デザインルーム | 木造軸組在来構法による既存建物を、外部より鋼製受け梁と鋼製筋かいフレームにより耐震補強をなす架構 |
| KR20120036842A (ko) * | 2009-05-12 | 2012-04-18 | 코닌클리케 필립스 일렉트로닉스 엔.브이. | 악성의 호르몬 민감성 전립선 암에 대한 마커로서의 포스포디에스테라제 4ｄ7 |
| WO2010131195A1 (en) * | 2009-05-12 | 2010-11-18 | Koninklijke Philips Electronics N.V. | Phosphodiesterase 4d7 as prostate cancer marker |
| CN102893392B (zh) | 2010-04-13 | 2015-08-05 | Gan系统公司 | 采用孤岛拓扑结构的高密度氮化镓器件 |
| GB201322034D0 (en) | 2013-12-12 | 2014-01-29 | Almac Diagnostics Ltd | Prostate cancer classification |
| GB201504763D0 (en) | 2015-03-20 | 2015-05-06 | Mironid Ltd | Compounds and uses |
| JP6745820B2 (ja) | 2015-05-29 | 2020-08-26 | コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． | 前立腺がん予後判定の方法 |
| CN105893782A (zh) * | 2016-05-26 | 2016-08-24 | 江苏省人民医院 | 前列腺癌风险预测装置 |
| GB201616439D0 (en) | 2016-09-28 | 2016-11-09 | Mironid Limited | Compounds and uses |
| CN106544430A (zh) * | 2016-11-04 | 2017-03-29 | 叶伟亮 | 一种检测前列腺癌的分子标记物及其应用 |
| US20210277479A1 (en) * | 2016-12-01 | 2021-09-09 | Koninklijke Philips N.V. | Risk scores based on human phosphodiesterase 4 d variant 7 expression |
| EP3450981A1 (en) * | 2017-08-28 | 2019-03-06 | Trizell GmbH | Btnl8 as a marker for tregs |
| SG11202003233YA (en) * | 2017-11-03 | 2020-05-28 | Oxford BioDynamics PLC | Genetic regulation of immunoresponse by chromosome interactions |
| DE102017125780B3 (de) * | 2017-11-05 | 2018-12-13 | Dimo Dietrich | Verfahren zur Bestimmung des Ansprechens einer malignen Erkrankung auf eine Immuntherapie |
| KR102080887B1 (ko) * | 2017-11-07 | 2020-02-24 | 고려대학교 산학협력단 | Gcc2 유전자 또는 단백질을 과발현하는 엑소좀 기반 폐암 진단 또는 예후 예측용 마커 조성물 |
| WO2019158825A1 (en) * | 2018-02-16 | 2019-08-22 | Tampereen Korkeakoulusäätiö SR | Xrcc5 as biomarker for prostate cancer |
| GB201805527D0 (en) | 2018-04-04 | 2018-05-16 | Mironid Ltd | Compounds and their use as pde4 activators |
| KR20220008175A (ko) * | 2020-07-13 | 2022-01-20 | 가톨릭대학교 산학협력단 | 전립선암 환자의 예후 진단 및 치료 전략 결정용 병리등급 특이적 마커 |
| CN112779348B (zh) * | 2020-12-31 | 2022-05-20 | 四川农业大学 | 一种小麦单位面积穗数主效qtl位点及紧密连锁的kasp引物和应用 |
| EP4360711A1 (en) * | 2022-10-27 | 2024-05-01 | Koninklijke Philips N.V. | Treatment of prostate cancer by promoting pde4d7 |
| WO2024088865A1 (en) | 2022-10-27 | 2024-05-02 | Koninklijke Philips N.V. | Treatment of prostate cancer by promoting pde4d7 |
| WO2025016918A1 (en) | 2023-07-18 | 2025-01-23 | Koninklijke Philips N.V. | Prediction of an outcome of a subject suffering from a glioma |
| EP4600377A1 (en) | 2024-02-12 | 2025-08-13 | Koninklijke Philips N.V. | Prediction of an outcome of a subject suffering from a glioma |
| EP4620461A1 (en) | 2024-03-22 | 2025-09-24 | Koninklijke Philips N.V. | Treatment of prostate cancer by inhibiting short pde4d isoforms |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5932465A (en) * | 1997-10-16 | 1999-08-03 | Icos Corporation | Phosphodiesterase 8A |
| US20090176722A9 (en) | 2000-01-28 | 2009-07-09 | Shiv Srivastava | Androgen-regulated PMEPA1 gene and polypeptides |
| PL364135A1 (en) | 2001-01-31 | 2004-12-13 | Pfizer Products Inc. | Nicotinamide biaryl derivatives useful as inhibitors of pde4 isozymes |
| IS7221A (is) * | 2001-11-15 | 2004-04-15 | Memory Pharmaceuticals Corporation | Hringlaga adenosínmónófosfat fosfódíesterasa 4D7 ísóform og aðferðir til notkunar þeirra |
| US20030220273A1 (en) | 2002-05-15 | 2003-11-27 | Isis Pharmaceuticals Inc. | Antisense modulation of phosphodiesterase 4D expression |
| WO2004042390A2 (en) | 2002-11-08 | 2004-05-21 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with human phosphodiesterase 4b (pde4b) |
| WO2004042389A2 (en) * | 2002-11-08 | 2004-05-21 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with human phosphodiesterase 4d (pde4d) |
| EP1426767A1 (en) | 2002-12-04 | 2004-06-09 | Bayer HealthCare AG | Diagnostics and therapeutics for diseases associated with human phosphodiesterase 4c (PDE4C) |
| CA2458085A1 (en) * | 2003-03-21 | 2004-09-21 | F. Hoffmann-La Roche Ag | Transcriptional activity assay |
| CA2521303A1 (en) * | 2003-04-10 | 2004-10-21 | F. Hoffmann-La Roche Ag | The use of pde4d in the screening for medicaments against atherosclerosis |
| US7250416B2 (en) * | 2005-03-11 | 2007-07-31 | Supergen, Inc. | Azacytosine analogs and derivatives |
| JP2009537118A (ja) | 2006-05-19 | 2009-10-29 | トピジェン・ファーマシューティカルズ・インコーポレーテッド | ホスホジエステラーゼの発現に影響するオリゴヌクレオチド |
| US9939441B2 (en) | 2006-07-21 | 2018-04-10 | Epigenomics Ag | Methods and nucleic acids for analyses for cellular proliferative disorders |
| CA2664630C (en) | 2006-10-10 | 2018-11-27 | Shiv Srivastava | Prostate cancer-specific alterations in erg gene expression and detection and treatment methods based on those alterations |
| EP3078751B1 (en) * | 2007-11-23 | 2018-08-01 | Epigenomics AG | Methods and uses of nucleic acids for the analysis of methylation and expression of genes, in particular of nfatc3, associated with prostate cell proliferative disorders |
| WO2010131195A1 (en) * | 2009-05-12 | 2010-11-18 | Koninklijke Philips Electronics N.V. | Phosphodiesterase 4d7 as prostate cancer marker |
| KR20120036842A (ko) * | 2009-05-12 | 2012-04-18 | 코닌클리케 필립스 일렉트로닉스 엔.브이. | 악성의 호르몬 민감성 전립선 암에 대한 마커로서의 포스포디에스테라제 4ｄ7 |
| BR112015020098B1 (pt) * | 2013-03-15 | 2020-10-27 | Iris International, Inc. | composição de agente de contraste de partículas para colorir uma amostra de fluido sanguíneo e método para tratar partículas de uma amostra de fluido sanguíneo |
-
2010
- 2010-05-11 WO PCT/IB2010/052073 patent/WO2010131195A1/en not_active Ceased
- 2010-05-11 EP EP10726251.1A patent/EP2430191B1/en active Active
- 2010-05-11 DK DK10726251.1T patent/DK2430191T3/en active
- 2010-05-11 BR BRPI1007093A patent/BRPI1007093A2/pt not_active Application Discontinuation
- 2010-05-11 JP JP2012510424A patent/JP6148007B2/ja active Active
- 2010-05-11 RU RU2011150279A patent/RU2651474C2/ru active
- 2010-05-11 KR KR1020117029715A patent/KR101778036B1/ko active Active
- 2010-05-11 CN CN201710192366.7A patent/CN107267482A/zh active Pending
- 2010-05-11 ES ES10726251T patent/ES2700877T3/es active Active
- 2010-05-11 US US13/320,283 patent/US8753892B2/en active Active
- 2010-05-11 EP EP18187420.7A patent/EP3434787B1/en active Active
- 2010-05-11 CN CN201080033823.4A patent/CN102549167B/zh active Active
-
2015
- 2015-09-25 JP JP2015188247A patent/JP6105012B2/ja active Active
-
2017
- 2017-03-13 JP JP2017046859A patent/JP6430560B2/ja active Active
-
2018
- 2018-10-31 JP JP2018205900A patent/JP2019059733A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017184729A5 (enExample) | ||
| JP2012526544A5 (enExample) | ||
| JP6415547B2 (ja) | 膵臓癌診断用組成物およびこれを用いた膵臓癌診断方法 | |
| US10408839B2 (en) | Biomarker panel for diagnosing cancer | |
| Wu et al. | PD-L1 detection on circulating tumor-derived extracellular vesicles (T-EVs) from patients with lung cancer | |
| JP6983221B2 (ja) | 大腸癌の併用検査 | |
| WO2012129325A1 (en) | Molecular analysis of tumor samples | |
| US20210310080A1 (en) | Composition for diagnosing cancer using potassium channel proteins | |
| JP6415546B2 (ja) | 脳卒中の鑑別診断を支援する方法 | |
| US20160003786A1 (en) | Methods Of Detecting Cancer | |
| Xu et al. | Identification of blood protein biomarkers that aid in the clinical assessment of patients with malignant glioma | |
| CA2857589C (en) | Biomarker-based methods and biochips for aiding the diagnosis of stroke | |
| JP2012526543A5 (enExample) | ||
| EP3428648B1 (en) | Method for assisting prediction of recurrence risk in hepatocellular carcinoma patient, and use of a kit | |
| EP3215851B1 (en) | Lung cancer sub-typing method | |
| JP2017526896A (ja) | 補体因子ｂタンパク質に特異的に結合する抗体及び糖鎖抗原１９−９タンパク質に特異的に結合する抗体を含む膵臓癌診断用キット | |
| JP7237587B2 (ja) | マーカー、ヒト精巣上体タンパク質４（ｈｅ４）に基づく肺腺癌の再発を検出する方法および関連する使用 | |
| EP2856166B1 (en) | Method for the diagnosis of mammals | |
| WO2016143805A1 (ja) | 膀胱がんの検出方法 | |
| JP2015078842A (ja) | 虚血性心疾患の評価方法、評価用キット及び評価装置 | |
| AU2018100578A4 (en) | Method for detection & diagnosis of oral cancer in a sample | |
| JP7126668B2 (ja) | 膠原病判定方法 | |
| CN119804865A (zh) | 细胞外囊泡蛋白质作为诊断腹主动脉瘤的生物标志物及应用 | |
| EP2963124A1 (en) | Biomarker combinations for use in pancreatic cancer screening | |
| KR20170097954A (ko) | 간암 진단 지표로서의 혈중 페리오스틴 |